There can be no guarantee that Gilenya will be submitted or approved for any extra indications or labeling in any market, Or at any primary time. Nor can there be any guarantee that Gilenya will achieve any particular levels of revenue later on in life. specifically, Management's expectations regarding Gilenya could have, amongst other things, dangerous clinical trial results, Including out-of-the-ordinary new clinical data and uncontrolled additional analysis of existing clinical data; rivals in general, Including potential competition from additional newly }
was given birth to on july 23
September 29th, 2014 at 05:10 pm